This infographic explores the emerging concepts of disease activity, disease stability, and disease control in COPD.
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
This infographic outlines how endotyping, phenotyping, and genotyping are interrelated concepts that are crucial for improving the way patients with COPD are characterized and how understanding these concepts can better optimize patient care

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.
Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.